AbbVie
Yahoo Finance • 7 hours ago
Prime Medicine stock soars amid gene editing sector momentum
Investing.com -- Prime Medicine (NASDAQ:PRME) stock rose 32%, extending recent gains following Eli Lilly’s (NYSE:LLY) acquisition deal for Verve Therapeutics (NASDAQ:VERV) last month. The gene editing company has seen its shares surge... Full story
Yahoo Finance • 20 hours ago
How AbbVie is Engineering Its Next Growth Phase
AbbVie (NASDAQ:ABBV) has emerged as one of the standout performers in the healthcare sector this year, with its stock climbing 6% while the broader S&P 500 healthcare index declined 1%. This outperformance reflects investor confidence in t... Full story
Yahoo Finance • yesterday
Guru Fundamental Report for ABBV
Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for... Full story
Yahoo Finance • yesterday
Notable healthcare headlines for the week: Novo Nordisk, Eli Lilly, AbbVie and Centene in focus
Wall Street notched another record close on Thursday, as market participants snapped up equities and dumped bonds after nonfarm payrolls jumped more than expected in June. The S&P 500 Health Care Index Sector (NYSEARCA:XLV [https://seekin... Full story
Yahoo Finance • 3 days ago
Validea Detailed Fundamental Analysis - ABBV
Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for... Full story
Yahoo Finance • 4 days ago
AbbVie sees negative Q2, full-year impact from IPR&D and milestones expense
[AbbVie] hapabapa/iStock Editorial via Getty Images * AbbVie (NYSE:ABBV [https://seekingalpha.com/symbol/ABBV]) said it will incur a negative impact of $0.42 to GAAP and non-GAAP diluted earnings per share in Q2 due to acquired IPR&D an... Full story
Yahoo Finance • 4 days ago
AbbVie updates 2025 earnings guidance to reflect $823 million IPR&D expense
AbbVie Inc . (NYSE:ABBV) announced Thursday that its expected second quarter 2025 GAAP and adjusted non-GAAP earnings will include a pre-tax acquired in-process research and development (IPR&D) and milestones expense of $823 million. This... Full story
Yahoo Finance • 5 days ago
ABBV Factor-Based Stock Analysis
Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for... Full story
Yahoo Finance • 6 days ago
US judge halts Trump administration move to layoff HHS employees
[US Department of Health and Human Services] MarioGuti/iStock via Getty Images A U.S. federal judge has put a stop to the Trump administration's plans to significantly downsize the workforce and close several agencies within the U.S. Depa... Full story
Yahoo Finance • 7 days ago
Sector Update: Health Care Stocks Higher Late Afternoon
Health care stocks rose late Monday afternoon with the NYSE Health Care Index up 0.4% and the Health PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story
Yahoo Finance • 7 days ago
Morgan Stanley reiterates Overweight rating on AbbVie stock at $250
Investing.com - Morgan Stanley has reiterated an Overweight rating and $250.00 price target on AbbVie (NYSE:ABBV), a prominent player in the Biotechnology industry with a market capitalization of $326.4 billion, following the company’s acq... Full story
Yahoo Finance • 7 days ago
AbbVie to buy Capstan for up to $2.1 billion in immunology push
By Christy Santhosh (Reuters) -AbbVie said on Monday it would acquire privately held cell therapy developer Capstan Therapeutics in a deal worth up to $2.1 billion, expanding its product pipeline with experimental treatments for autoimmun... Full story
Yahoo Finance • 7 days ago
Palantir, Circle Internet Surge Among Monday's Market Cap Stock Movers
Monday’s trading session has seen notable movements in the stock market, with some stocks experiencing significant intra-day volatility. Mega-cap stock Palantir Technologies Inc (NASDAQ:PLTR) has soared following a strategic partnership... Full story
Yahoo Finance • 7 days ago
AbbVie to Host Second-Quarter 2025 Earnings Conference Call
NORTH CHICAGO, Ill., June 30, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its second-quarter 2025 financial results on Thursday, July 31, 2025, before the market opens. AbbVie will host a live webcast of the earnings conference... Full story
Yahoo Finance • 7 days ago
AbbVie to acquire Capstan Therapeutics for up to $2.1B in cash
[Abbvie] vzphotos/iStock Editorial via Getty Images AbbVie (NYSE:ABBV [https://seekingalpha.com/symbol/ABBV]) has agreed to acquire clinical-stage biotechnology company Capstan Therapeutics for up to $2.1 billion in cash. The transaction... Full story
Yahoo Finance • 7 days ago
AbbVie Agrees to Acquire Capstan Therapeutics for $2.1 Billion
BUSINESS AbbVie agreed to acquire Capstan Therapeutics, including its lead asset, for $2.1 billion in cash. The North Chicago, Ill., drugmaker’s planned acquisition includes CPTX2309, which is currently in Phase 1 and in development for th... Full story
Yahoo Finance • 7 days ago
AbbVie to buy Capstan Therapeutics for up to $2.1 billion
(Reuters) -U.S. drugmaker AbbVie said on Monday it will acquire cell therapy developer Capstan Therapeutics in a cash deal worth up to $2.1 billion. Capstan develops CAR-T therapies, a type of treatment that uses a patient's own immune ce... Full story
Yahoo Finance • 7 days ago
FDA accepts Allergan's application for neck line treatment
IRVINE, Calif. - The U.S. Food and Drug Administration has accepted for review Allergan Aesthetics’ supplemental premarket approval application for SKINVIVE by JUVEDERM to reduce neck lines, the AbbVie company (NYSE:ABBV) announced Monday.... Full story
Yahoo Finance • 7 days ago
AbbVie to Acquire Capstan Therapeutics, Further Strengthening Commitment to Transforming Patient Care in Immunology
Capstan's lead asset, CPTX2309, is a targeted lipid nanoparticle (tLNP) that delivers an mRNA encoding an anti-CD19 chimeric antigen receptor (CAR) to CD8-expressing cytotoxic T cells in vivo, and is a potential first-in-class product for... Full story
Yahoo Finance • 7 days ago
U.S. Food and Drug Administration Accepts for Review Allergan Aesthetics Premarket Approval Application for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance
SKINVIVE by JUVÉDERM® is currently approved in the U.S. as the first and only hyaluronic acid microdroplet injectable indicated to improve cheek skin smoothness. If approved, SKINVIVE by JUVÉDERM® will be the first hyaluronic acid injecta... Full story
